SAN DIEGO, Calif-NewBiotics, Inc announced January 8, that H. Michael Shepard, will be the company's president.
Shepard will be responsible for overseeing all aspects of the company's research and development strategies, scientific and corporate collaborations, and related activities.
NewBiotics, a developer of drugs targeted against cancer and infectious disease, is privately held. The company's drugs use a "Trojan horse solution" to fight various diseases.
Shepard, who previously worked for Canji, and Genentech, helped develop the p53gene product for cancer therapy.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.